Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Retired, I can't find any evidence that Roaring Kitty has endorsed Amarin.
Sleven,
Ramfan, Does anyone else have a method of use patent, that covers icosapent ethyl, for migraine treatment?
Sleven,
Captain, Let me know if you get a response.
Thanks.
Sleven,
Captain,
https://www.sciencedirect.com/science/article/pii/S0889159124003003
Journal publication.
Sleven,
JRoon, Good advice. I doubt he takes it.
Sleven,
Nuke, I think you misunderstand my post. Kiwi is criticizing our current management for not running more clinical trials. I am actually defending both current and past management. I think it would be a waste of money to run any more trials to prove the value of icosapent ethyl for cardiovascular risk reduction.
Do you disagree?
You made your decision about who you think should be running the company, and your not whining about what they are doing. I have no problem with what I have seen current management do to date.
Sleven,
Kiwi, By the way. This new management team is who you endorsed.
Sleven,
Kiwi, If you want the company to make different decisions, talk to them. I can only track decisions that they make. How long did it take for statin drugs to gain traction? You apparently don't believe that the drug has clinical value. I do. Generic competition is forcing the price cuts. This is killing our margins and profit in the US. Is this a surprise for you? I believe both past and current management understand how to deal with this problem. Supply chain will be the key
Once again I urge you to sell your position and move to a company that you can understand.
Sleven,
Chromosome, I think you and I have a similar mindset. I look forward to more conversations. Enjoy your weekend as well.
Sleven,
Chromosome, I agree with your opinion about the European market. It's a time issue. As far as the infringement suite goes, the court of appeals can't actually make any rulings that directly effect either party. They are simply making a determination about the dismissal by the lower court. If they send it back, the suit picks up where it left off.
Sleven,
RMB, I agree.
Sleven,
Chromosome, If you hadn't I was going to give you a link to the audio. It sounded like the court was going to remand this.
Sleven,
Chromosome, Have you listened to the oral arguments at the circuit?
Sleven,
Kiwi, What you think the company should do is irrelevant. We are investors not board members. We don't get a vote. You and I have access to the same information. We disagree about the outcome. If you are convinced that the Vascepa market won't grow, sell your position.
Sleven,
Jasbg, Incorrect. I still find your ignorance offensive.
Sleven,
Kiwi, l don't think any more studies are required. The scientific committee understands the value of icosapent ethyl. This is not my opinion. I make this statement based on medical treatment guidelines. France and Italy have both backed Vazkepa. They just don't want to pay for it. I do a fair amount of reading. To me this looks like an economic issue, not a scientific/medical debate. Eventually the math should resolve this in our favor. The cost of prevention is less than the cost of post event treatment. Germany never had any intentions of reimbursement. I base this on the comparator drug. They will avoid the expense as long as they can. Eventually they will be forced to pay up. The adoption of new medical therapy is a top down process.
Sleven,
Kiwi, I will get beck to you to tomorrow.
Sleven,
Kiwi, No disagreement. Some posters here seem to think that because Alex Denner is a billionaire biotech investor, he can do no wrong. He must be acting in the best interest of the average shareholder. Factual information of prior misdeadeads will not change their minds. Does that remind you of any other currently relevant situation?
Sleven,
Jasbg, You went to school on the short bus, I assume.
Sleven,
Kiwi, Yes. Everyone tossed bricks at me when I said giving control to Sarisa might be a bad idea. Now what do you think. I still believe the science will play out in our favor.
Sleven,
Tat, Got it. So a non shareholder with a negative outlook. Can't disagree about Denner concerns.
Sleven,
Tat, Based on your opinion and wording, "off your backs", I assume you are not a shareholder. Do you have a short position? No need to respond if you don't want to.
Sleven,
Kiwi, Fair enough. You know I'm not an Alex Denner fan. That aside, they are following the plan laid out by prior management. I think the plan is sound. It's not going to be quick. I'm not sure if the UK courts will approve the share repurchase. EU market will expand in time. The three remaining big five markets will reimburse eventually. Guidance dictates that. This earnings call should not have surprised anyone. The next catalyst should be the ruling from the court of appeals.
Sleven,
Kiwi, What is the point of waiting? Sell now and take the small loss.you don't own many shares. Move on to greener pastures.
Sleven,
Tat, The appellate court can only make a determination about the the ruling from the district court. Was that ruling correct based on the relevant law? The practices of insurance companies don't meet the legal definition of direct infringement. It is inducement.
Sleven,
Canam, Sorry. I only answered half of your question. The judges are not still deliberating. Cases are discussed after the arguments. What takes time is writing the order.
Sleven,
Canam, Non precedential rulings usually come about a month after oral arguments. If the ruling is precedential it's usually about three.
Sleven,
Stockboy, Yes. Our discussion is over.
Sleven,
Stockboy, Have you considered the possibility, that no one else is "grasping this", might be because you are wrong?
Sleven,
North, I think my debate with stockboy has come to a conclusion. I would be interested to hear your thoughts about the effects of a remand in the Hikma inducement case. If my math is correct, treble damages could be more than the current Market cap of Hikma corporation.
Sleven,
Stockboy, That's fine with me. You should start a letter writing campaign with the lawyers that represent Amarin. Clearly you understand the law and biochemistry at a level they can't comprehend.
Sleven,
Stockboy, I understand why you disagree, and I respect your passion. But you are not correct. Icosapent ethyl is no longer an ethyl ester at the point where it is absorbed by the body.
Sleven,
Stockboy, EPA is the active moiety. Legally it doesn't matter that icosapent ethyl is an ethyl ester of that moiety. The same thing would apply to a self emulsifying variation. The active part of the molecule, that relates to medical benefits, is EPA. A patent on a self emulsifying version would prevent the generic companies from selling their own version. It doesn't have a legal effect on prior art.
Sleven,
RMB, That is about how the drug is metabolized. My understanding. If I am incorrect, I would appreciate someone correcting me.
Sleven,
RMB, Icosapent ethyl is an ethyl ester of EPA. EPA is a molecule that is naturally produced. Icosapent ethyl requires a bit of chemistry. This distinction was part of our complaint to the ITC. Any ethyl ester should not be considered a dietary supplement. They are actually unapproved drugs. Google ethyl ester. That should explain the process for you.
Sleven,
Luck, Infringement is part of the generic business model. That's why the lawyer, representing Hikma, was so concerned about the downstream effect of this case moving past the pleading phase. The Hatch Waxman act was poorly drafted and implemented. Since it's introduction in 1984, (from memory) section 8 has given these companies free reign to infringe on valid method of use patents. GSK v Teva opened a door. If the federal circuit remands this case, we should all read the wording carefully.
Sleven,